Do healing peptides like BPC-157 actually regrow tissue, or just reduce inflammation?

BPC-157 research investigates more than inflammation. Rat injury experiments report effects on early functional recovery and blood-vessel formation, while tendon-cell work explores growth-related signaling. These findings offer possible repair mechanisms. However, “regrows tissue” is a much stronger clinical claim: it would require convincing evidence of restored human tissue structure and function, not simply a change in cell activity or an animal healing score.[1][2]

Human reports are much less conclusive. A small retrospective knee-pain report described improvement after BPC-157, sometimes combined with another peptide, but lacked a randomized placebo comparison. Reported pain relief does not show that cartilage, tendon, or ligament regenerated, and it cannot reliably separate treatment effects from other causes of improvement. An injection into a painful joint is also not evidence for every type of injury or delivery route.[3]

Inflammation and repair are interconnected, so the choice is not simply “regeneration or symptom relief.” A useful human trial would assess pain alongside validated function, appropriate structural measurements, durability, and adverse events against a suitable control. Until that evidence is available, proposed repair pathways should be described as preclinical findings rather than established human tissue regeneration.[1][2][3]